Table 3.
Differences of risk factors and clinical findings between the two outcome groups
| Variable | Poor outcome | Favorable outcome | Test Value | P Value |
|---|---|---|---|---|
| (n = 100) | (n = 151) | |||
| Age, y, median (IQR) | 75 (70, 78.75) | 72 (66, 75) | 3.658a | < 0.001 |
| Male, n (%) | 58 (58.0) | 80 (53.0) | 0.612c | 0.434 |
| Smoking, n (%) | 24 (24.0) | 38 (25.2) | 0.044c | 0.834 |
| Hypertension, n (%) | 83 (83.0) | 113 (74.8) | 2.344c | 0.126 |
| Diabetes mellitus, n (%) | 23 (23.0) | 29 (19.2) | 0.527c | 0.468 |
| Hyperlipidemia, n (%) | 14 (14.0) | 29 (19.2) | 1.148c | 0.284 |
| Congestive heart failure, n (%) | 30 (30.0) | 22 (14.6) | 8.721c | 0.003 |
| Baseline SBP (mm Hg, ‾x ± s) | 149.6 ± 24.5 | 143.5 ± 19.0 | 2.113b | 0.036 |
| Baseline DBP (mm Hg, ‾x ± s) | 87.9 ± 14.1 | 85.0 ± 12.6 | 1.707b | 0.089 |
| Baseline NIHSS score, median (IQR) | 15 (11, 19) | 4 (2, 7) | 11.150a | < 0.001 |
| Moderate-severe LA, n (%) | 39 (39.0) | 24 (15.9) | 17.084c | < 0.001 |
| sICH, n (%) | 17 (17.0) | 10 (6.6) | 6.749c | 0.009 |
| nsICH, n (%) | 30 (30.0) | 16 (10.6) | 15.133c | < 0.001 |
| SAP, n (%) | 66 (66.0) | 13 (8.6) | 63.224c | < 0.001 |
| Anticoagulant therapy, n (%) | 56 (56.0) | 64 (42.4) | 0.022c | 0.881 |
| Stroke recurrence, n (%) | 4 (4.0) | 4 (2.6) | 0.004c | 0.953 |
| Laboratory findings, mmol/l | ||||
| Total cholesterol (‾x ± s) | 4.1 ± 0.9 | 4.1 ± 0.8 | 0.703b | 0.482 |
| Triglyceride (‾x ± s) | 1.0 ± 0.4 | 1.3 ± 0.9 | -2.843b | 0.005 |
| LDL-C (‾x ± s) | 2.3 ± 0.7 | 2.2 ± 0.7 | 1.412b | 0.152 |
| Fasting glucose (‾x ± s) | 7.0 ± 2.7 | 5.8 ± 1.7 | 3.844b | < 0.001 |
a Kruskal-Wallis H test; bt test; cχ2 test.